Biologic Treatment in Sjögren's Syndrome

Pablo Ruiz Sada; David Isenberg; Coziana Ciurtin


Rheumatology. 2015;54(2):219-230. 

In This Article


We screened the literature from 1994 to 2014 using the Medline database and the following MeSH terms: Sjögren's syndrome, biologic therapies, B cell targeted therapy, rituximab, belimumab, epratuzumab, T cell modulation therapy, abatacept and interferon. We selected only English publications and included randomized controlled trials (RCTs), observational studies and case reports of adult patients. For additional explanations about the rational for using biologic therapies and disease pathogenesis, we selected relevant papers using the MeSH terms: Sjögren's syndrome, B cells, T cells, B cell activating factor (BAFF), transgenic mice, non-obese diabetic mice, gene expression, CD6, CD22, lymphotoxin beta, fms-like tyrosine kinase etc. We will not discuss here the available evidence regarding the efficacy of symptomatic and conventional immunosuppressive therapy in SS, as it is beyond the scope of this review.